VRTX Stock Recent News

There's a simple explanation for Vertex's glaring Q2 loss. The company raised its full-year product revenue guidance.

Vertex Pharmaceuticals, Inc. (NASDAQ:VRTX ) Q2 2024 Earnings Conference Call August 1, 2024 4:30 PM ET Company Participants Reshma Kewalramani - Chief Executive Officer, President Stuart Arbuckle - Chief Operating Officer Charlie Wagner - Chief Financial Officer. Susie Lisa - Senior Vice President, Investor Relations Conference Call Participants Salveen Richter - Goldman Sachs David Risinger - Leerink Partners Jessica Fye - J.P.

Vertex Pharmaceuticals (VRTX) came out with a quarterly loss of $12.83 per share versus the Zacks Consensus Estimate of a loss of $11.50. This compares to earnings of $3.89 per share a year ago.

Vertex Pharmaceuticals raised its annual revenue forecast on Thursday, betting on robust demand for its cystic fibrosis (CF) treatments.

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the second quarter ended June 30, 2024, and raised its full year product revenue guidance to $10.65 to $10.85 billion. “Vertex delivered another strong quarter of revenue growth coupled with outstanding execution across the business, and we are increasing our full year product revenue guidance,” said Reshma Kewalramani, M.D., Chief Executive Officer, and President of Ver.

Investing cash in great businesses can set your portfolio up for long-term success. Vertex is paving a profitable path from a portfolio of existing and likely blockbusters.

LOS ANGELES--(BUSINESS WIRE)--Prime Therapeutics Fails to Silence AHF in PBM Price-Fixing Arbitration.

Vertex's (VRTX) second-quarter revenues are expected to have been driven by the robust sales of its lead CF product, Trikafta/Kaftrio.

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Vertex (VRTX), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2024.

These businesses are on very different growth trajectories in opposite industries, but each can have something to offer the long-term investor. Vertex Pharmaceuticals is building out a pipeline of potential blockbusters that could rival its current portfolio.